SCHEMBL650086

SCHEMBL650086

Brc1ccc(-c2nc3ccccc3nc2-c2ccccc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.64
KDM4E B2RXH2 5/20 0.64
LMNA P02545 4/20 0.64
TDP1 Q9NUW8 2/20 0.64
KMT2A Q03164 2/20 0.64
GAA P10253 2/20 0.64
MEN1 O00255 1/20 0.64
ALDH1A1 P00352 5/20 0.58
MAPK1 P28482 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58
PKM P14618 1/20 0.55
AKT1 P31749 1/20 0.55
AKT2 P31751 1/20 0.55
MAPK14 Q16539 2/20 0.53
MAPK13 O15264 1/20 0.53
GCGR P47871 1/20 0.53
MAPK12 P53778 1/20 0.53
MAPK11 Q15759 1/20 0.53
THRB P10828 1/20 0.51
ADORA2A P29274 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30476324 1.00 L3MBTL1 (0.64) L3MBTL1KDM4ELMNATDP1KMT2A
SCHEMBL652142 0.96 L3MBTL1 (0.57) L3MBTL1KDM4ELMNATDP1KMT2A
SCHEMBL31510226 0.96 L3MBTL1 (0.57) L3MBTL1KDM4ELMNATDP1KMT2A
SCHEMBL23606773 0.92 L3MBTL1 (0.56) L3MBTL1KDM4ELMNATDP1KMT2A
SCHEMBL24036921 0.89 L3MBTL1 (0.57) L3MBTL1KDM4ELMNATDP1KMT2A
SCHEMBL5476339 0.89 ALDH1A1 (0.67) L3MBTL1KDM4ELMNATDP1KMT2A
SCHEMBL5475289 0.89 ALDH1A1 (0.67) L3MBTL1KDM4ELMNATDP1KMT2A
SCHEMBL13950894 0.89 KDM4E (0.78) L3MBTL1KDM4ELMNATDP1KMT2A
SCHEMBL12317104 0.87 ALDH1A1 (0.56) L3MBTL1KDM4ELMNATDP1KMT2A
SCHEMBL13726198 0.86 KDM4E (0.75) L3MBTL1KDM4ELMNATDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116239576-A Indole derivative and application thereof 浙江八亿时空先进材料有限公司 2023-06-09 CN disclosed
WO-2021230651-A1 ORGANIC ELECTRONIC ELEMENT COMPRISING COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, AND ELECTRONIC DEVICE THEREOF 덕산네오룩스 주식회사 2021-11-18 WO disclosed
CN-112538061-A Organic electroluminescent compound based on symmetric aromatic amine structure 南京高光半导体材料有限公司 2021-03-23 CN disclosed
EP-2067778-B1 Quinoxaline derivative, and light emitting element, light emitting device and electronic appliance using the same SEMICONDUCTOR ENERGY LAB (JP) 2016-08-17 EP disclosed
EP-2067778-B1 Quinoxaline derivative, and light emitting element, light emitting device and electronic appliance using the same SEMICONDUCTOR ENERGY LAB (JP) 2016-08-17 EP disclosed
US-9056883-B2 Organometallic complex, light-emitting element, light-emitting device, electronic device, and lighting device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2015-06-16 US disclosed
US-9056883-B2 Organometallic complex, light-emitting element, light-emitting device, electronic device, and lighting device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2015-06-16 US disclosed
US-9056883-B2 Organometallic complex, light-emitting element, light-emitting device, electronic device, and lighting device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2015-06-16 US disclosed
EP-2065378-B1 Quinoxaline derivate, and light-emitting element, light-emitting device, and electronic device using quinoxaline derivative SEMICONDUCTOR ENERGY LAB (JP) 2015-01-28 EP disclosed
EP-2065378-B1 Quinoxaline derivate, and light-emitting element, light-emitting device, and electronic device using quinoxaline derivative SEMICONDUCTOR ENERGY LAB (JP) 2015-01-28 EP disclosed
US-20080097094-A1 DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS ABBOTT LABORATORIES (US) 2008-04-24 US disclosed
US-7319106-B2 Diazabicyclic central nervous system active agents ABBOTT LABORATORIES (US) 2008-01-15 US disclosed
WO-2007108403-A1 QUINOXALINE DERIVATIVE, AND LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, ELECTRONIC DEVICE USING THE QUINOXALINE DERIVATIVE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2007-09-27 WO disclosed
WO-2007108403-A1 QUINOXALINE DERIVATIVE, AND LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, ELECTRONIC DEVICE USING THE QUINOXALINE DERIVATIVE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2007-09-27 WO disclosed
US-20070222374-A1 Quinoxaline derivative, and light-emitting element, light-emitting device, electronic device using the quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2007-09-27 US disclosed
US-20070222374-A1 Quinoxaline derivative, and light-emitting element, light-emitting device, electronic device using the quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2007-09-27 US disclosed
US-20070222374-A1 Quinoxaline derivative, and light-emitting element, light-emitting device, electronic device using the quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2007-09-27 US disclosed
US-6809105-B2 (CIS)-6-(3-PYRIDINYL)-3,6-DIAZABICYCLO(3.2.0) HEPTANE FOR EXAMPLE; ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, ATTENTION DEFICIT HYPERACTIVITY DISORDER, DEPRESSION, NICOTINIC WITHDRAWAL SYNDROME, TOURETTE'S SYNDROME, AND SCHIZOPHRENIA ABBOTT LABORATORIES 2004-10-26 US disclosed
US-20040186107-A1 Diazabicyclic central nervous system active agents ABBVIE INC. 2004-09-23 US disclosed
US-20020019388-A1 Diazabicyclic central nervous system active agents ABBVIE INC. 2002-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080097094-A1 DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS GAP43, GABRE, CHRNA6 L3MBTL1 4557/4885KDM4E 4017/4885LMNA 2377/4885
US-20020019388-A1 Diazabicyclic central nervous system active agents GAP43, GABRE, CHRNA6 L3MBTL1 4394/4885KDM4E 3864/4885LMNA 2415/4885
US-20040186107-A1 Diazabicyclic central nervous system active agents GAP43, GABRE, CHRNA6 L3MBTL1 4394/4885KDM4E 3864/4885LMNA 2415/4885
US-20070222374-A1 Quinoxaline derivative, and light-emitting element, light-emitting device, electronic device using the quinoxaline derivative NDUFA9, MT-ND1, NQO2 L3MBTL1 1414/4885KDM4E 2330/4885LMNA 2348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.